in vitro News and Research

RSS

Essen BioScience, Nycomed partner to develop modulators of voltage-gated ion channels

Essen BioScience Inc. - a specialty provider of cell-based assay solutions and contract research services - and Nycomed - a privately owned global pharmaceutical company headquartered in Zurich, Switzerland - are pleased to announce a joint discovery agreement to identify novel small molecule ion channel modulators as pain therapeutics.

From Sartorius 21 Jun 2010

NanoViricides' anti-Dengue drug candidates demonstrate potential against severe virus infection

NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant protection in the initial animal survival studies of Dengue virus infection. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.

21 Jun 2010

Phase IIb EMBLEM study results of epratuzumab in patients with SLE presented at EULAR 2010

Immunomedics Inc. today announced that clinical trial results from the Phase IIb EMBLEM study of epratuzumab, a monoclonal antibody targeting CD22, in patients with moderate-severe systemic lupus erythematosus were presented at the 2010 annual Congress of the European League Against Rheumatism in Rome, Italy.

21 Jun 2010

Positive preclinical data on Aeterna Zentaris' AEZS-130/Ghrelin Receptor Agonist presented at ENDO meeting

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that a poster on its oral synthetic growth hormone secretagogue/ghrelin receptor agonist, AEZS-130, was presented yesterday at the 92nd Annual Endocrine Society (ENDO) Meeting and Expo, which is held through June 22, 2010 at the San Diego Convention Center in San Diego, California.

21 Jun 2010

Preclinical study shows treatment with DAS181 inhibits infection with multiple HPIV strains

NexBio, Inc. announced today the publication of a "Major Article" in the Journal of Infectious Diseases of a preclinical study showing that treatment with DAS181 (Fludase) inhibits infection with multiple human parainfluenza virus strains. DAS181 is a broad spectrum host-targeted investigational drug candidate for treatment and prevention of Influenza-Like Illness.

19 Jun 2010

Investigators discover new way to harness thrombin's anti-blood clotting properties

In research led by a Saint Louis University investigator, molecular biologists have discovered a way to harness the enzyme thrombin's anti-blood clotting properties. The finding opens the door to new medications that will treat diseases related to thrombosis, the presence of blood clots in blood vessels, which is responsible for nearly a third of all deaths in the U.S.

19 Jun 2010

CardioGenics Holdings files Certificate of Change with the Secretary of State of Nevada

CardioGenics Holdings Inc., developer of the ultra-sensitive QL Care Point-Of-Care analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced today that the Company has filed a Certificate of Change with the Secretary of State of Nevada, which implements a share consolidation of the Company's authorized and outstanding common stock on a ten (old) for one (new) basis.

19 Jun 2010

Children's Hospital Boston receives $2.4M Gates Foundation grant to develop novel neonatal vaccines

Children's Hospital Boston announced today that it has received a $2.4 million grant from the Bill & Melinda Gates Foundation. The grant will support the development of novel vaccines for newborns – research that is spearheaded by Ofer Levy, MD, Ph.D., a principal investigator in the Division of Infectious Diseases at Children's.

18 Jun 2010

Inspire's TIGER-1 Phase 3 clinical trial data with denufosol for CF presented at 33rd ECFS

Inspire Pharmaceuticals, Inc. announced today that data is being presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during an oral presentation and poster presentations at the 33rd Annual European Cystic Fibrosis Society (ECFS) Conference June 16 - 19, 2010 in Valencia, Spain.

18 Jun 2010

Vitrolife acquires 25% participation in HertART Aps

Vitrolife has entered an agreement with the Danish company HertART Aps with regard to product development and distribution of IVF products and at the same time acquires a participation of 25 percent in the company.

18 Jun 2010

An ubiquitin-specific peptidase that potentially promote cancer cell necrosis

"ubiquitin-specific peptidase 21 (USP21) has been identified as another essential player in regulation of tumor necrosis factor alpha (TNF-alpha)-induced nuclear factor kappaB (NF-kappaB) activation by working on receptor-interacting protein 1(RIP1)."

18 Jun 2010

Bayer, OncoMed collaborate to develop anti-cancer stem cell therapeutics to target Wnt signaling pathway

Bayer Schering Pharma AG and OncoMed Pharmaceuticals, Inc., today announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway.

17 Jun 2010

FDA seeks public input on regulation of laboratory-developed tests

The U.S. Food and Drug Administration today announced plans to hold a public meeting on July 19-20, 2010, to discuss how the agency will oversee laboratory-developed tests (LDTs).

17 Jun 2010

Researchers assess effect of MDs on cardiac and endothelial cell proliferation, survival

A research team from McGill University (Canada) report a beneficial effect on cardiac function in mouse models when implanted monocytes - a type of white blood cell that is part of the immune system - helped preserve cardiac function following a heart attack (myocardial infarction).

17 Jun 2010

Fertility drugs cause multiple and premature births

The widespread use of fertility drugs, not just high-tech laboratory procedures, plays a major role in causing multiple births and contributes to the problem of premature birth in the United States, experts said today at the March of Dimes National Communications Advisory Council luncheon.

17 Jun 2010

Oncodesign announces technology license agreement with Janssen Pharmaceutica

Oncodesign Biotechnology(R) announced today that it has signed a licensing agreement with Janssen Pharmaceutica NV (hereinafter Janssen) related to Janssen’s macrocyclic chemistry technology. Oncodesign will have exclusive access to this technology for six years.

16 Jun 2010

Animal-free testing method for human-specific allergenicity displayed at 2010 ICCA-LRI & JRC Workshop

For the first time, Sweden-based Biovator AB and its cooperation partners will reveal the crucial aspects of the company's unique, animal-free testing method for human-specifi c allergenicity. A detailed presentation is being created for participants in the 2010 ICCA-LRI & JRC Workshop (International Council of Chemical Associations Long-Range Research Initiative), which will take place June 16-17, 2010 at the Grand Hotel Bristol in Stresa, Italy.

16 Jun 2010

Epocal receives FDA marketing clearance for new lactate test on epoc Blood Analysis System

Epocal, Inc., a leading edge provider of point of care technology, announced today that it has received U.S. Food and Drug Administration (FDA) clearance to market its new lactate test on the epoc Blood Analysis System. Lactate measurements from the epoc System are used to evaluate acid-base status and for diagnosis and treatment of lactic acidosis (abnormally high acidity of the blood).

15 Jun 2010

CDI, Promega enter collaboration for toxicity testing in drug discovery process

Cellular Dynamics International (CDI) and Promega have entered into a research collaboration with the goal of bringing more relevant and highly predictive toxicity testing to the drug discovery process. Pharmaceutical discovery scientists will now be able to combine bioassays with human cardiomyocytes to improve prediction of unintentional, detrimental side effects that have previously remained undetected until late in the development process or after release of the drug to the general public.

15 Jun 2010

Tel Aviv University research suggests link between IVF treatments and autism

The first "test tube baby" was born in 1978. With advances in reproductive science, an estimated one percent of all American babies are now born each year through in vitro fertilization. But IVF and other assisted fertility treatments may be solving one problem by creating another, suggests new evidence from Tel Aviv University.

15 Jun 2010

in vitro News and Research

Essen BioScience, Nycomed partner to develop modulators of voltage-gated ion channels

NanoViricides' anti-Dengue drug candidates demonstrate potential against severe virus infection

Phase IIb EMBLEM study results of epratuzumab in patients with SLE presented at EULAR 2010

Positive preclinical data on Aeterna Zentaris' AEZS-130/Ghrelin Receptor Agonist presented at ENDO meeting

Preclinical study shows treatment with DAS181 inhibits infection with multiple HPIV strains

Investigators discover new way to harness thrombin's anti-blood clotting properties

CardioGenics Holdings files Certificate of Change with the Secretary of State of Nevada

Children's Hospital Boston receives $2.4M Gates Foundation grant to develop novel neonatal vaccines

Inspire's TIGER-1 Phase 3 clinical trial data with denufosol for CF presented at 33rd ECFS

Vitrolife acquires 25% participation in HertART Aps

An ubiquitin-specific peptidase that potentially promote cancer cell necrosis

Bayer, OncoMed collaborate to develop anti-cancer stem cell therapeutics to target Wnt signaling pathway

FDA seeks public input on regulation of laboratory-developed tests

Researchers assess effect of MDs on cardiac and endothelial cell proliferation, survival

Fertility drugs cause multiple and premature births

Oncodesign announces technology license agreement with Janssen Pharmaceutica

Animal-free testing method for human-specific allergenicity displayed at 2010 ICCA-LRI & JRC Workshop

Epocal receives FDA marketing clearance for new lactate test on epoc Blood Analysis System

CDI, Promega enter collaboration for toxicity testing in drug discovery process

Tel Aviv University research suggests link between IVF treatments and autism

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News